Skip to main content
    K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $121.52
    -4.33 (-3.44%)

    Market Cap: $10.74B

    Last updated: Nov 17, 2026 at 4:35 PM ET

    Kymera Therapeutics Inc (KYMR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Kymera Therapeutics (KYMR) has a market cap of $10.74B and an enterprise value of $10.37B. It kept -341.78% of revenue as net income over the last 12 months. Revenue grew 133.77% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 3.48% below the market cap, as cash exceeds debt.

    Market Cap$10.74B
    Enterprise Value$10.37B
    Latest price (Nov 17, 2026)$121.52

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.96% in the quarter ended Sep 30, 2026 and grew 14.67% a year over 2 years.

    Shares Outstanding100.10M
    Shares Change (YoY)+14.66%
    Shares Change (QoQ)+1.96%
    Share Count Growth (2Y CAGR)+14.67%

    Valuation Ratios

    Sales and book value multiples are 119.0x and 7.5x. Its year-end P/S ranged from 18.9x to 160.7x from 2020 to 2025.

    P/S Ratio119.0x
    Forward P/S108.1x
    P/B Ratio7.5x

    Valuation history and multiples

    Price Statistics

    The stock is up 87.13% over 52 weeks and trades 3.51% above its 50-day average.

    Beta (1Y)0.95
    52-Week Change+87.13%
    1-Month Change+12.45%
    3-Month Change-4.55%
    6-Month Change+55.52%
    5-Year Change+115.06%
    Total Return (1Y)+87.13%
    Total Return (3Y CAGR)+84.22%
    Total Return (5Y CAGR)+14.41%
    Return vs SPY (1Y)+77.40%
    Max Drawdown (1Y)-27.74%
    Max Drawdown (3Y)-59.83%
    Sharpe Ratio (1Y)1.09
    Correlation with SPY (1Y)0.22
    50-Day Average$117.40
    200-Day Average$99.94
    52-Week Range$63.69 to $142.92
    RSI (14 Days)47.8
    Average Volume (20 Days)1.01M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 11.13x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio11.13x
    Quick Ratio11.13x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -21.64% over the last 12 months, against a 5-year average of -27.42%.

    Return on Equity (ROE)-21.64%
    Return on Assets (ROA)-19.77%
    Return on Capital Employed (ROCE)-20.83%
    ROE (5Y Average)-27.42%
    ROA (5Y Average)-21.70%
    ROIC (5Y Average)-15.57%
    Asset Turnover0.07x
    Receivables Turnover10.22x

    Scores

    KYMR has an Altman Z-Score of 46.75, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score46.75
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $102.24M over the last 12 months.

    Revenue$102.24M
    Revenue Growth (YoY)+133.77%
    Gross Profit$102.24M
    Operating Income-$404.89M
    Pretax Income-$349.43M
    Net Income-$349.43M
    EBITDA-$341.32M
    EBIT-$349.43M
    Reported EPS (TTM)-$3.62

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 90.96% of the $1.77B in total assets.

    Cash and Equivalents$373.37M
    Total Debt$0
    Net Cash$373.37M
    Net Cash Per Share$3.73
    Working Capital$908.87M
    Shareholder Equity$1.61B
    Book Value Per Share$16.13
    Total Assets$1.77B
    Total Liabilities$152.74M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.33M of capital spending, operating cash flow left -$288.89M of free cash flow.

    Operating Cash Flow-$287.56M
    Capital Expenditures$1.33M
    Free Cash Flow-$288.89M
    FCF Per Share-$3.51
    Depreciation and Amortization$8.11M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -396.03%.

    Gross Margin100.00%
    Operating Margin-396.03%
    Pretax Margin-341.78%
    Net Margin-341.78%
    EBITDA Margin-333.85%
    EBIT Margin-341.78%
    FCF Margin-282.57%

    Growth

    Revenue fell 5.74% a year over 3 years.

    Revenue Growth (3Y CAGR)-5.74%
    Revenue Growth (5Y CAGR)+2.87%
    Book Value Per Share Growth (2Y CAGR)+66.54%
    Tangible Book Per Share Growth (2Y CAGR)+66.54%

    Revenue and profit by year

    Dividends and Yields

    KYMR does not pay a dividend. Its free cash flow yield is -2.38%.

    FCF Yield-2.38%
    Buyback Yield-0.76%
    Shareholder Yield-0.76%

    Peer Position

    Against 8 similar companies, KYMR has the highest P/S.

    P/S Ratio119.0x vs 13.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)+133.77% vs +49.59% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 3.53% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+3.53%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About KYMR

    What is KYMR's market cap?

    Kymera Therapeutics has a market cap of $10.74B. Its enterprise value, which adds debt and subtracts cash, is $10.37B.

    How many shares of KYMR are outstanding?

    Kymera Therapeutics has 100.10M shares outstanding. The count is up 14.66% from a year earlier.

    Does KYMR pay a dividend?

    No. Kymera Therapeutics does not pay a dividend.

    How much debt does KYMR have?

    Kymera Therapeutics has $0 of total debt and $373.37M of cash and equivalents, a net cash position of $373.37M.